Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments.

BMC cancer - 4 Jul 2014

Rawlinson Rebecca, Massey Andrew J

Abstract excerpt

BACKGROUND: Chk1 inhibitors are currently in clinical trials in combination with a range of cytotoxic agents and have the potential to potentiate the clinical activity of a large number of standard of care chemotherapeutic agents. Utilizing pharmacodynamic biomarkers to optimize drug dose and scheduling in these trials could greatly enhance the likelihood of clinical success. METHODS: In this study, we evaluated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Checkpoint Kinase 1
Share to DNA Damage
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Histones

Share to Pharmacogenetics

Share to Protein Kinase Inhibitors

Share to Protein Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 24996846
DOI: 10.1186/1471-2407-14-483
PMCID: PMC4094550

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments.PMID 24996846Read ↗

CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells.Semantic proximity Read ↗

Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells.Semantic proximity Read ↗

CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications.Semantic proximity Read ↗

CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons <i>In vitro</i> and <i>In vivo</i>Semantic proximity Read ↗

Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.Semantic proximity Read ↗

Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agentsSemantic proximity Read ↗

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.Semantic proximity Read ↗

The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human NeuroblastomaSemantic proximity Read ↗

Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer CellsSemantic proximity Read ↗

Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivoSemantic proximity Read ↗

p53‐dependent G1 arrest in 1st or 2nd cell cycle may protect human cancer cells from cell death after treatment with ionizing radiation and Chk1 inhibitorsSemantic proximity Read ↗

High-throughput screening reveals higher synergistic effect of MEK inhibitor combinations in colon cancer spheroidsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.